LRGUK Inhibitors
LRGUK inhibitors belong to a specialized class of chemical compounds designed to target and modulate the activity of the enzyme LRGUK (Leucine-Rich Repeat-containing G Protein-Coupled Receptor Kinase). LRGUK is a member of the G protein-coupled receptor kinase (GRK) family, which plays a crucial role in regulating cellular responses to various external stimuli. These inhibitors are meticulously crafted to interact with the active site of LRGUK, thereby hindering its enzymatic function. The structural design of LRGUK inhibitors involves intricate molecular modifications to ensure a specific and high-affinity binding to the target enzyme.
The development of LRGUK inhibitors is rooted in the exploration of signaling pathways and their modulation for potential applications in various physiological processes. Researchers focus on understanding the intricate details of LRGUK's role in cellular signaling cascades and aim to design inhibitors that can selectively modulate its activity. The chemical class of LRGUK inhibitors encompasses diverse structures, each with unique features tailored to optimize binding affinity and specificity to the LRGUK enzyme. The ongoing research in this field is dedicated to elucidating the structural-activity relationships of these inhibitors, aiming to refine their pharmacological properties further. As our understanding of LRGUK and its cellular functions continues to deepen, the development and optimization of LRGUK inhibitors represent a promising avenue for advancing our knowledge of cellular signaling mechanisms and their potential implications in various biological contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases, which can inhibit various kinases that phosphorylate LRGUK, potentially reducing its activity by preventing phosphorylation-dependent activation or localization. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a phosphoinositide 3-kinases (PI3K) inhibitor that can impede the PI3K/AKT pathway. Since LRGUK may be regulated through PI3K/AKT signaling, inhibition of this pathway can decrease LRGUK activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that can disrupt the mTOR signaling pathway. Because LRGUK function could be associated with mTOR pathway activation, rapamycin may indirectly decrease LRGUK activity by inhibiting downstream signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MAPK/ERK inhibitor that can block the activation of MEK1/2, thus inhibiting ERK activation. If LRGUK is regulated by the MAPK/ERK pathway, U0126 may diminish LRGUK activity by preventing its phosphorylation or signaling through this cascade. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor which can prevent activation of p38-dependent pathways. If LRGUK is regulated through p38 MAPK signaling, this inhibitor could reduce LRGUK activity by blocking signaling events upstream of LRGUK's functional engagement. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another PI3K inhibitor that acts through a different mechanism than LY294002. By inhibiting PI3K, wortmannin could indirectly lead to decreased LRGUK activity if LRGUK is involved in PI3K/AKT signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which prevents the activation of MAPK/ERK pathway. If LRGUK activity is influenced by ERK signaling, PD98059 could reduce LRGUK's functional activity by inhibiting this pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can block JNK signaling. As such, if LRGUK is regulated in part by the JNK pathway, its activity could be decreased by SP600125 through inhibition of this stress-related kinase pathway. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
Bafilomycin A1 is a specific inhibitor of the vacuolar-type H+-ATPase. If LRGUK function is dependent on endosomal-lysosomal acidification or trafficking, Bafilomycin A1 may indirectly inhibit LRGUK activity by disrupting these processes. | ||||||
Gö 6983 | 133053-19-7 | sc-203432 sc-203432A sc-203432B | 1 mg 5 mg 10 mg | $105.00 $299.00 $474.00 | 15 | |
Go6983 is a broad-spectrum protein kinase C (PKC) inhibitor. If PKC isoforms are involved in the regulation or activation of LRGUK, this compound could lead to reduced functional activity of LRGUK by inhibiting PKC-mediated signaling. | ||||||